Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInjection and Intravenous Infusion Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent AdministrationCPT cpt-96406-intralesional-chemotherapy-more-than-7-lesions
    Ask Trek AI about this page

    CPT 96406: Intralesional Chemotherapy for >7 Lesions

    Medicare pays $137 and commercial payers pay $217 on average nationally for this procedure.

    CPT code 96406 describes intralesional chemotherapy administration when a provider injects chemotherapeutic agent(s) directly into a lesion or tumor and documents treatment of more than seven lesions; this represents a procedural oncology service typically performed in an outpatient oncology clinic or physician office as part of lesion-directed cancer therapy.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for cpt 96406 policy alerts

    Get alerted when payer policies referencing 96406 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    Medicare's mean rate of $137.4 sits slightly below BUCA's average commercial mean of $217, illustrating a notable gap between government and aggregated commercial pricing for CPT 96406. The commercial mean landscape varies: Blue Cross Blue Shield's mean is substantially above both, while Aetna and Cigna cluster below UnitedHealth Group and BCBS, positioning BUCA between commercial extremes and Medicare.

    Dispersion measured by the interquartile range (P75−P25) is widest for Blue Cross Blue Shield at $194 ($380.2−$168.6), followed by BUCA at $167 ($286.9−$122.0) and UnitedHealth Group at $99.4 ($192.6−$93.2). The tightest spreads are Aetna at $89 ($112.0−$22.0) and Cigna at $116.1 ($183.0−$64.6), indicating Blue Cross Blue Shield and BUCA have the greatest variability in commercial payments while Aetna shows the most compressed middle 50%.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 68-year-old male with multiple cutaneous metastatic deposits from malignant melanoma presents to an outpatient oncology infusion suite for targeted local therapy. The oncologist evaluates several subcutaneous and dermal nodules and selects intralesional chemotherapy to treat numerous cutaneous lesions in a single session. The procedure involves sterile preparation of the skin, local anesthesia as needed, and direct injection of chemotherapy into each tumor. Because more than seven lesions will be treated, billing is reported with 96406. Typical workflow includes pre-procedure verification of diagnosis (for example C43.9 or C44.99), informed consent, documentation of lesion count and locations, photographic or diagrammatic lesion mapping, medication preparation by pharmacy, intralesional injections by the treating Hematology & Oncology or Medical Oncology physician, post-procedure observation for immediate adverse effects, and discrete documentation supporting the number of lesions treated and the agent administered. Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, or ambulatory surgical centers where local tumor-directed injections are performed.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96405

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0003X
    207RX0202X
    207ZP0102X
    246ZA2600X
    1835P1300X
    261QA1903X
    385HR2050X
    282N00000X

    Related ICD-10-CM Codes

    19 rows

    ICD-10-CM CodeDescription
    C43.21Malignant melanoma of right ear and external auricular canal
    C43.9Malignant melanoma of skin, unspecified
    C44.212Basal cell carcinoma of skin of right ear and external auricular canal
    C44.219Basal cell carcinoma of skin of left ear and external auricular canal
    C44.42Squamous cell carcinoma of skin of scalp and neck
    C44.511Basal cell carcinoma of skin of breast
    C44.519Basal cell carcinoma of skin of other part of trunk
    C44.611Basal cell carcinoma of skin of unspecified upper limb, including shoulder
    C44.619Basal cell carcinoma of skin of left upper limb, including shoulder
    C44.699Other specified malignant neoplasm of skin of left upper limb, including shoulder

    Showing 1–10 of 19

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    VonvendiCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    CPT-96401-SUBCUTANEOUS-INTRAMUSCULAR-CHEMOTHERAPY-ADMINISTRATION

    CPT 96401: Subcutaneous or Intramuscular Nonhormonal Chemotherapy

    CPT-96402-SUBCUTANEOUS-INTRAMUSCULAR-HORMONAL-ANTINEOPLASTIC-ADMINISTRATION

    CPT 96402: Subcutaneous/Intramuscular Hormonal Anti‑Neoplastic Administration

    CPT-96405-INTRALESIONAL-CHEMOTHERAPY-ONE-TO-SEVEN-LESIONS

    CPT 96405: Intralesional Chemotherapy, 1–7 Lesions

    CPT-96409-INTRAVENOUS-PUSH-CHEMOTHERAPY-INITIAL-DRUG

    CPT 96409: Intravenous Push Chemotherapy, Single/Initial Drug

    CPT-96411-ADD-ON-INTRAVENOUS-PUSH-CHEMOTHERAPY-DRUG

    CPT 96411: Add-On IV Push for Additional Chemotherapy Drug

    CPT-96413-INTRAVENOUS-CHEMOTHERAPY-INFUSION-INITIAL-HOUR

    CPT 96413: Intravenous Chemotherapy Infusion, Initial Hour

    CPT-96415-ADDITIONAL-HOUR-CHEMOTHERAPY-INTRAVENOUS-INFUSION

    CPT 96415: Continued Intravenous Chemotherapy Infusion, Per Additional Hour

    CPT-96416-CHEMOTHERAPY-INITIATION-PORTABLE-IMPLANTABLE-PUMP

    CPT 96416: Initiation of Intravenous Chemotherapy via Pump

    CPT-96417-ADD-ON-IV-CHEMOTHERAPY-INFUSION-DIFFERENT-AGENT

    CPT 96417: Continued Intravenous Chemotherapy Administration

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Chemotherapy administration; intralesional, up to and including 7 lesions
    Use when intralesional chemotherapy treats 7 or fewer lesions; 96406 is reported when more than 7 lesions are treated.